
Index of Microcirculatory Resistance: *The Basics*

William F. Fearon, MD

Associate Professor of Medicine

Director, Interventional Cardiology

Stanford University Medical Center



Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship

- Grant/Research Support
- Consulting Fees/Honoraria
- Major Stock Shareholder/Equity
- Royalty Income
- Ownership/Founder
- Intellectual Property Rights
- Other Financial Benefit

Company


- St. Jude Medical, Medtronic, NHLBI
- Medtronic

- Minor stock options: HeartFlow




Assessment of the Microvasculature

Diagnostic Challenge



Assessment of the Microvasculature

Diagnostic Challenge




Assessment of the Microvasculature

- Extremely challenging diagnosis
 - Heterogeneous patient population
 - Variety of pathogenetic mechanisms
 - Poor anatomic resolution
 - Potentially patchy nature of the disease
- Therefore, assessment of the microvasculature is primarily *functional* and not *anatomic*



Evaluating the Microcirculation... *...in the Cath Lab*

TIMI Myocardial Perfusion Grade:



Evaluating the Microcirculation...

...in the Cath Lab

TIMI Myocardial Perfusion Grade:

- Easy to obtain

- Specific for microvasculature

- Predictive of outcomes in large studies

Drawbacks:


- Qualitative

- Interobserver variability


- Not as useful in smaller studies



Doppler Wire Coronary Flow Reserve




$$CFR = \frac{\text{Hyperemic Flow}}{\text{Resting Flow}}$$



Coronary Wire-Based Assessment


Coronary Flow Reserve



- Not microvascular specific
- No clearly defined normal value
- Affected by resting hemodynamics



Index of Microcirculatory Resistance




Index of Microcirculatory Resistance

Potential Advantages:


- ❑ Readily available in the cath lab
- ❑ Specific for the microvasculature
- ❑ Quantitative and reproducible
- ❑ Predictive of outcomes



Estimation of Coronary Flow



Calculation of mean transit time




Derivation of IMR:

- Resistance = Δ Pressure / Flow
- Δ Pressure = $P_d - P_v$ Flow $\cong 1 / T_{mn}$
- $IMR = P_d - P_v / (1 / T_{mn})$
- $IMR = P_d \times T_{mn}$ *at maximal hyperemia...*




Practical Measurement of IMR




IMR Case Example

Cardiac transplant recipient enrolled in study evaluating ACE inhibition



IMR Case Example

Cardiac transplant recipient enrolled in study evaluating ACE inhibition




Accessing IMR



Flushing the System



Resting T_{mn} Measurements



Hyperemic T_{mn} Measurements



Calculating IMR

$$\text{IMR} = P_d \times \text{Hyp } T_{mn}$$


$$\text{IMR} = 59 \times 0.39$$

$$\text{IMR} = 23$$


**RADI
VIEW**




Animal Validation of IMR




Animal Validation of IMR



Animal Validation of IMR



Animal Validation of IMR



Reproducibility of IMR

Effect of Pacing on FFR/CFR/IMR

| | Baseline | RV Pacing at 110 bpm |
|--------|-----------------|-----------------------|
| CFR | 3.1 ± 1.1 | $2.3 \pm 1.2 \dagger$ |
| IMR, U | 21.8 ± 6.5 | 22.9 ± 6.9 |
| FFR | 0.88 ± 0.07 | 0.87 ± 0.07 |

Effect of Blood Pressure on FFR/CFR/IMR

| | Baseline | Nitroprusside |
|--------|-----------------|-----------------|
| CFR | 2.9 ± 0.9 | 2.5 ± 1.2 |
| IMR, U | 23.85 ± 6.1 | 24.00 ± 7.9 |
| FFR | 0.88 ± 0.04 | 0.87 ± 0.05 |


Change in LV Contractility and FFR/CFR/IMR

| | Baseline | Dobutamine |
|--------|-----------------|-----------------------|
| CFR | 3.0 ± 1.0 | $1.7 \pm 0.6 \dagger$ |
| IMR, U | 22.2 ± 6.0 | 23.6 ± 8.2 |
| FFR | 0.88 ± 0.06 | 0.87 ± 0.06 |




Reproducibility of IMR

Mean correlation coefficients of IMR, CFR and FFR values comparing baseline measurement with each hemodynamic intervention



Reproducibility of IMR

Coefficient of variation between pairs of baseline values of IMR and CFR



Reproducibility of IMR

Correlation between IMR and cardiac MR assessment of microvascular obstruction in 108 patients after STEMI

- Repeated IMR measurements obtained by 4 different operators in 12 STEMI patients were highly correlated ($r=0.99$, $P<0.001$), with a mean difference between IMR measurements of 0.01 (mean standard error 1.59 [95% CI -3.52 to 3.54], $P=0.48$).



IMR: *Normal Value*

An IMR ≤ 25 is considered normal

- The mean IMR measured in 15 subjects (22 arteries) without any evidence of atherosclerosis and no/minimal risk factors was 19 ± 5 .
- The mean IMR measured in 18 subjects with normal stress tests and normal coronary angiography was 18.9 ± 5.6 .




IMR and Epicardial Stenosis

Role of collaterals when measuring IMR in patients with significant epicardial stenosis


- Resistance = Pressure / Q_{myo}
- $Q_{\text{myo}} = Q_{\text{cor}} + Q_{\text{coll}}$
- Simplified IMR = $P_d \times T_{\text{mn}}$
- But T_{mn} is inversely proportional to *coronary flow*



Importance of Collaterals when Measuring IMR



Importance of Collaterals when Measuring IMR



Flow ↓'s more than it should, T_{mn} ↑'s and $IMR_{app} = P_d \times T_{mn}$ ↑'s


To measure true IMR, must measure coronary wedge pressure to incorporate collateral flow

$$IMR = P_d \times T_{mn} \times (FFR_{cor} / FFR_{myo})$$




IMR is not affected by epicardial stenosis severity:

Animal Validation




IMR is not affected by epicardial stenosis severity:

Human Validation



IMR is not affected by epicardial stenosis severity:

Human Validation




Estimating True IMR without Wedge

- $IMR = P_d \times T_{mn} \times (FFR_{cor} / FFR_{myo})$
- $IMR = P_d \times T_{mn} \times ((P_d - P_w) / (P_a - P_w) / (P_d / P_a))$
- **If there is a relationship between FFR_{cor} and FFR_{myo} , perhaps we can estimate FFR_{cor} without having to measure the coronary wedge pressure.**




Estimating True IMR without Wedge

In a derivation cohort of 50 patients, a strong linear relationship was found between FFR_{cor} and FFR_{myo} .




Estimating True IMR without Wedge

In a validation cohort of 72 patients, there was no significant difference in IMR with estimate FFR_{cor} or measured FFR_{cor} .




Estimating True IMR without Wedge

In a validation cohort of 72 patients, there was no significant difference in IMR with estimate FFR_{cor} or measured FFR_{cor} .




Clinical Application of IMR

59 year old man with HTN, dyslipidemia and chest pain with emotional stress and septal ischemia on Nuclear Scan



$$\text{IMR} = 76 \times 0.70 = 53$$

**RADI
VIEW**



(89)

Pa mean

(76)

Pd mean

0.85

FFR

2.9

CFR

-0.05


dT

5.04

CURSOR



RESET



Chest Pain and “Normal Coronaries”

- 139 patients referred for coronary angiography because of symptoms and/or abnormal stress test and found to have “normal” appearing coronaries
- FFR, IMR, CFR, IVUS and acetylcholine challenge were performed down the LAD



Chest Pain and “Normal Coronaries”

| Patient Characteristic | n=139 |
|-------------------------------|--------------|
| Age (years) | 54 ±11 |
| Female | 77% |
| Hypertension | 53% |
| Diabetes | 23% |
| Dyslipidemia | 63% |
| Tobacco Use | 8% |



Chest Pain and “Normal Coronaries”

- The mean IMR was 19.6 ± 9.1
- Microvascular dysfunction was present in 21% (defined as $\text{IMR} \geq 25$)
- Predictors of microvascular dysfunction were age, diabetes, HTN, and BMI




Chest Pain and “Normal Coronaries”

- 5% of patients had an FFR of the LAD ≤ 0.80
 - 44% had epicardial endothelial dysfunction
 - 58% had a myocardial bridge
-
- 24% had nonischemic FFR, normal IMR, no endothelial dysfunction and no “bridge”




IMR Before PCI in Stable Patients

IMR measured before PCI in 50 stable patients undergoing LAD PCI




Predictive Value of IMR after PCI for STEMI

IMR predicts peak CK in patients with STEMI



IMR and Outcomes post STEMI

Multicenter study evaluating relationship between IMR and longer-term outcomes in 253 STEMI patients




No. at risk:

| | | | | |
|----------|-----|-----|-----|----|
| IMR ≤ 40 | 173 | 154 | 149 | 84 |
| IMR > 40 | 80 | 69 | 63 | 33 |




IMR post Stem Cell Therapy

IMR measured in 15 patients with ischemic cardiomyopathy before and 6 months after intracoronary stem cell delivery



IMR post Statin Therapy


IMR measured after PCI in 80 patients randomized to either 1 month pretreatment with pravastatin or placebo




IMR post ACE Inhibitor Therapy

40 patients randomized to IC enalaprilat or placebo prior to PCI

Enalaprilat



Placebo



Limitations of IMR

- Invasive
- Interpatient and intervessel variability?
 - Sensor distance
- Independent of epicardial stenosis
 - Coronary wedge pressure



Conclusion

Take Home Messages:

- The microvasculature is a complex entity, which is challenging to investigate.
- Measurement of IMR is easy, specific for the microvasculature, quantitative, reproducible, and independent of hemodynamic changes.
- Measurement of IMR may help guide treatment in patients with “normal coronaries” and chest pain. IMR predicts outcomes in acute MI; emerging data suggest its utility in stable PCI patients, as well.

